Evidence-Based Reviews

Brain/body connection: Treating depression in patients with cardiovascular disease

Current Psychiatry. 2004 March;3(3):20-34

References

1. Cassem N, Hackett T. Psychiatric condition in a coronary care unit. Ann Intern Med 1971;75:9-14.

2. Glassman A, Shapiro P. Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.

3. Carney R, Freedland K, Sheline Y, Weiss E. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol 1997;20:196-200.

4. Katon W, Schulbert H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237-47.

5. Lesperance F, Frasure-Smith N, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-60.

6. Connerney I, Shapiro P, McLaughlin J, et al. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet 2001;358:1766-71.

7. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.

8. Rugulies R. Depression as a predictor for coronary heart disease. Am J Prev Med 2002;23:51-61.

9. Wulsin L, Singal B. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003;65:201-10.

10. Carney R, Rich M, Freedland K, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-33.

11. Ladwig K, Roll G, Breithardt G, Borggrefe M. Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction. Am Heart J 1999;137:528-34.

12. Levine J, Covino N, Slack W, et al. Psychological predictors of subsequent medical care among patients hospitalized with cardiac disease. J Cardiopulm Rehabil 1996;16:109-16.

13. Lesperance F, Frasure-Smith N, Talajic M, Bourassa M. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002;105:1049-53.

14. Dwight M, Stoudemire A. Effects of depressive disorders on coronary artery disease: a review. Harv Rev Psychiatry 1997;5:115-122.

15. Penninx B, Beekman A, Honig A, et al. Depression and cardiac mortality. Arch Gen Psychiatry 2001;58:221-7.

16. Writing committee of the ENRICHD investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA 2003;289:3106-16.

17. Carney RM, Freedland K, Miller G, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002;53:897-902.

18. Musselman D, Evans D, Nemeroff C. The relationship of depression to cardiovascular disease. Arch Gen Psychiatry 1998;55:580-92.

19. Kop WJ. Chronic and acute psychological risk factors for clinical manifestations of coronary artery disease. Psychosom Med 1999;61:476-86.

20. Miller G, Cohen S, Herbert T. Pathways linking major depression and immunity in ambulatory female patients. Psychosom Med 1999;61:850-60.

21. Carney R, Freedland K, Stein P. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med 2000;62:639-47.

22. Carney R, Freedland K, Miller G, Jaffe A. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002;53:897-902.

23. Alexopoulos G, Meyers B, Young R, et al. Vascular depression hypothesis. Psychosom Med 1997;58:113-121.

24. Ziegelstein R, Fauerbach J, Stevens S, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160:1818-23.

25. Glassman AH, O’Connor C, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.

26. Ko D, Hebert P, Coffey C, et al. B-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.

Major depression is also associated with excessive sympathetic and diminished parasym-pathetic nervous system activity, potentially contributing to hypertension, increased resting heart rate, decreased heart rate variability, and altered endothelial function.^2,21,22 Each of these factors facilitates arterial plaque formation.

Depression may also exacerbate chronic anxiety and other forms of distress. The combined effects of an overtaxed central nervous system, neuroendocrine dysregulation, and unhealthy behaviors may eventually overwhelm the cardiovascular system.

CVD’s effect on depression. How does CVD contribute to depression? The vascular depression hypothesis²³ proposes that diffuse heart and brain atherosclerosis restricts perfusion of limbic and cortical structures that regulate mood. A first depressive episode after acute MI or CABG probably represents exacerbation of cerebrovascular insufficiency that preceded the coronary event.

Table

Four keys to effectively treat depression in patients with heart disease

Monitor depressive symptom severity Provide adequate trials of SSRIs to maximum tolerable dosages before switching to another agent Combine medications and psychotherapy whenever possible Collaborate closely with the primary care physician

In practical terms, this means that pathways linking depression and heart disease include not only biological factors but also:

psychological factors such as depression, anxiety, and chronic stress
behavioral factors such as smoking, physical inactivity, and high-fat diet.

How to improve outcomes

Patients with CVD commonly do not receive effective depression treatment:

Internists and family physicians give preferential attention to physical illness.
Patients may have insufficient access to mental health specialists.
Physicians do not adequately monitor depression treatment.
Patients are reluctant to accept the stigma of mental illness.

By collaborating with primary care physicians, you can improve the likelihood that depression treatment will achieve remission and prevent relapse (Table).

Risk factors for CVD. Depression contributes to heart disease by exacerbating four major CVD risk factors—smoking, diabetes, obesity, and physical inactivity. By effectively treating depression, you may help patients avoid common depressive symptoms—such as overeating and sedentary behaviors—that are related to low energy or fatigue.

Educate middle-aged patients with depression about CVD’s associated risk. Prochaska’s “stages of change” (see Related resources) can help them stop smoking, lose weight, and exercise.

Access to cardiac care. Depressed patients may be less motivated than nondepressed patients to pursue cardiac care.²⁴ Therefore, you may need to:

encourage your patients to take advantage of indicated state-of-the-art care, including stents, bypass surgery, and medications
understand patients’ complex cardiac regimens and help them adhere when depression interferes with their motivation.

Effective depression treatment

Patient history. For depressed patients older than 40, take a careful inventory of CVD risk factors:

family history of heart disease before age 60 for men and age 70 for women
personal history of smoking, blood pressure >140/90 mm Hg, LDL cholesterol >100 mg/dL, type 2 diabetes, body mass index >30, or physical inactivity (<30 minutes of walking 3 days a week).

In general, the more risk factors, the greater the risk of CVD.

Antidepressant selection. Selective serotonin reuptake inhibitors (SSRIs) are safe and effective for treating major depression in CVD and congestive heart failure.²⁵ Venlafaxine at doses >300 mg/d may increase blood pressure, so use this drug with caution in depressed patients with hypertension.

No controlled clinical trials have gauged the safety and efficacy of bupropion or mirtazapine in patients with CVD.

Tricyclic antidepressants are contraindicated for 6 months post-MI because they may contribute to arrhythmias. Avoid using them in depressed patients with CVD or conduction defects because of their quinidine-like effects on conduction.

Cardiac medications. Contrary to folk wisdom, beta blockers do not cause depression.²⁶ Whether or not a patient is depressed, our primary care and cardiology colleagues can use beta blockers to help regulate the peripheral autonomic nervous system, reducing high blood pressure and the risk of arrhythmias.

SSRIs may increase blood levels of beta blockers, warfarin, and other cardiac medications via cytochrome P-450 isoenzyme inhibition. Make sure warfarin levels and other cardiac drug effects are well monitored when you adjust psychotropic dosages.

Divalproex and SSRIs also may reduce platelet aggregation. Patients who are receiving concomitant aspirin or warfarin may bruise or bleed easily and require dosage reductions or medication changes.

Psychotherapy. All patients with major or minor depression and CVD are considered high-risk and are candidates for a trial of brief psychotherapy. Therapeutic goals are to achieve full remission of depressive symptoms as rapidly as possible, prevent relapse, and maximize adherence to cardiac and depression drug regimens.

Collaborate closely with the cardiologist or primary care physician during the patient’s depressive episode and occasionally during maintenance treatment. Discuss or share notes on the patient’s depressive and cardiac disorders, medication management, symptom monitoring, and behavior changes needed to reduce cardiac risk.